
Cingulate (CING) Stock Forecast & Price Target
Cingulate (CING) Analyst Ratings
Bulls say
Cingulate is a clinical-stage biopharmaceutical company that utilizes its drug delivery platform technology to develop once-daily tablets of multi-dose therapies, with an initial focus on ADHD and anxiety. While receiving a Complete Response Letter from the FDA for its lead asset, CTx-1301, is not ideal, the lack of safety or efficacy concerns bodes well for potential future approval after addressing Chemistry, Manufacturing and Controls (CMC) requests. With a current valuation that is attractive and the potential for significant upside, the risks of balance sheet/liquidity concerns, regulatory approvals, and competition should be considered. The company's focused approach on ADHD and its strong pipeline of potential treatments in this area, along with commercial readiness initiatives, make it a promising investment opportunity.
Bears say
Cingulate is facing an uphill battle with their ADHD and anxiety-focused drug delivery products, as evidenced by a lowered EPS estimate to $(1.81), with recent raising of funds likely only sustaining operations until 2027. Despite this market potential being quite large and the estimated ADHD medication sales growing year-over-year, the company's strength in this space is uncertain and could lead to a negative outlook on their stock.
This aggregate rating is based on analysts' research of Cingulate and is not a guaranteed prediction by Public.com or investment advice.
Cingulate (CING) Analyst Forecast & Price Prediction
Start investing in Cingulate (CING)
Order type
Buy in
Order amount
Est. shares
0 shares